{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:02Z","timestamp":1787009582306,"version":"build-2736575974"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>There is no consensus on the optimal perioperative management of patients on buprenorphine (BUP) for opioid use disorder (OUD). This article will review the available literature on BUP and the analgesic efficacy of BUP combined with full mu-opioid agonists and discuss the conflicting management strategies in the context of acute pain and our institution\u2019s protocol for the periprocedural management of BUP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched published data on BUP periprocedural management from inception through March 2018 without language restrictions. Study selection included publications reporting outcomes on perioperative pain management in OUD patients maintained on BUP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our search resulted in four case reports supporting periprocedural discontinuation of BUP and two case series, one secondary observational study, one prospective matched cohort study, and four retrospective cohort studies supporting periprocedural continuation of BUP. No clinical trials were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maintaining BUP perioperatively does not lead to worsened clinical outcomes. Patients can receive adequate pain control from mu-opioid agonists while maintained on BUP. Based upon available evidence, we recommend continuing BUP at a reduced dose when indicated to avoid withdrawal symptoms and to facilitate the analgesic efficacy of mu-opioid agonists administered in combination for acute postoperative pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pm\/pny217","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T02:46:28Z","timestamp":1537584388000},"page":"1395-1408","source":"Crossref","is-referenced-by-count":77,"title":["Perioperative Management of Buprenorphine: Solving the Conundrum"],"prefix":"10.1093","volume":"20","author":[{"given":"Aurora Naa-Afoley","family":"Quaye","sequence":"first","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"2021031606214318200_pny217-B1","author":"Hedden","year":"2015"},{"key":"2021031606214318200_pny217-B2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"2021031606214318200_pny217-B3","author":"CDC\/NCHS","year":"2017"},{"issue":"10","key":"2021031606214318200_pny217-B4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Medical Care"},{"key":"2021031606214318200_pny217-B5","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"2021031606214318200_pny217-B6","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"2021031606214318200_pny217-B7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"New Engl J Med"},{"issue":"3","key":"2021031606214318200_pny217-B8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","article-title":"Buprenorphine: Considerations for pain management","volume":"29","author":"Johnson","year":"2005","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"2021031606214318200_pny217-B9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-144-2-200601170-00010","article-title":"Acute pain management for patients receiving maintenance methadone or buprenorphine therapy","volume":"144","author":"Alford","year":"2006","journal-title":"Ann Intern Med"},{"key":"2021031606214318200_pny217-B10","year":"2016"},{"issue":"6","key":"2021031606214318200_pny217-B11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/ALN.0000000000001633","article-title":"To stop or not, that is the question: Acute pain management for the patient on chronic buprenorphine","volume":"126","author":"Anderson","year":"2017","journal-title":"Anesthesiology"},{"issue":"3","key":"2021031606214318200_pny217-B12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/pm\/pny019","article-title":"Patients maintained on buprenorphine for opioid use disorder should continue buprenorphine through the perioperative period","volume":"20","author":"Lembke","year":"2018","journal-title":"Pain Med"},{"issue":"5","key":"2021031606214318200_pny217-B13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: Ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2021031606214318200_pny217-B14","first-page":"29","article-title":"Buprenorphine: A (relatively) new treatment for opioid dependence","volume":"2","author":"Welsh","year":"2005","journal-title":"Psychiatry (Edgmont)"},{"issue":"5","key":"2021031606214318200_pny217-B15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200969050-00006","article-title":"Buprenorphine\/naloxone: A review of its use in the treatment of opioid dependence","volume":"69","author":"Orman","year":"2009","journal-title":"Drugs"},{"key":"2021031606214318200_pny217-B16","doi-asserted-by":"crossref","first-page":"170.","DOI":"10.3389\/fpsyt.2014.00170","article-title":"The kappa opioid receptor: From addiction to depression, and back","volume":"5","author":"Lalanne","year":"2014","journal-title":"Front Psychiatry"},{"issue":"2","key":"2021031606214318200_pny217-B17","first-page":"4","article-title":"Major depressive disorder and kappa opioid receptor antagonists","volume":"1","author":"Li","year":"2016","journal-title":"Transl Perioper Pain Med"},{"issue":"7","key":"2021031606214318200_pny217-B18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2021031606214318200_pny217-B19","volume-title":"SAMHSA\/Treatment Improvement Protocol 63. Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"issue":"2","key":"2021031606214318200_pny217-B20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/AJP.0b013e31815ca2b4","article-title":"Buprenorphine: New tricks with an old molecule for pain management","volume":"24","author":"Heit","year":"2008","journal-title":"Clin J Pain"},{"issue":"5","key":"2021031606214318200_pny217-B21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"issue":"1","key":"2021031606214318200_pny217-B22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009127009703700106","article-title":"Bioavailability of sublingual buprenorphine","volume":"37","author":"Mendelson","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"1\u20133","key":"2021031606214318200_pny217-B23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.11.052","article-title":"Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain","volume":"507","author":"Christoph","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"2021031606214318200_pny217-B24","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"2021031606214318200_pny217-B25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","article-title":"Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: A preliminary study","volume":"23","author":"Zubieta","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"2021031606214318200_pny217-B26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5055\/jom.2007.0018","article-title":"Use and misuse of buprenorphine in the management of opioid addiction","volume":"3","author":"Cicero","year":"2007","journal-title":"J Opioid Manag"},{"issue":"3","key":"2021031606214318200_pny217-B27","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2021031606214318200_pny217-B28","year":"2017"},{"key":"2021031606214318200_pny217-B29","year":"2018"},{"key":"2021031606214318200_pny217-B30","year":"2007"},{"issue":"18","key":"2021031606214318200_pny217-B31","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2165\/11208250-000000000-00000","article-title":"Buprenorphine 5, 10 and 20 mug\/h transdermal patch: A review of its use in the management of chronic non-malignant pain","volume":"71","author":"Plosker","year":"2011","journal-title":"Drugs"},{"key":"2021031606214318200_pny217-B32","year":"2010"},{"issue":"1","key":"2021031606214318200_pny217-B33","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain\u2014safety aspects","volume":"2","author":"Likar","year":"2006","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"2021031606214318200_pny217-B34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00520-006-0169-8","article-title":"Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients","volume":"15","author":"Mercadante","year":"2007","journal-title":"Supportive Care Cancer"},{"issue":"1","key":"2021031606214318200_pny217-B35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000349917","article-title":"The use of high dosages of transdermal buprenorphine for pain management in palliative cancer patients: A case study","volume":"6","author":"Clement","year":"2013","journal-title":"Case Rep Oncol"},{"issue":"6","key":"2021031606214318200_pny217-B36","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1185\/03007990902920731","article-title":"The role of transdermal buprenorphine in the treatment of cancer pain: An expert panel consensus","volume":"25","author":"Pergolizzi","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2021031606214318200_pny217-B37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/pme.12011","article-title":"A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain","volume":"14","author":"Mitra","year":"2013","journal-title":"Pain Med"},{"key":"2021031606214318200_pny217-B38","year":"2015"},{"issue":"5","key":"2021031606214318200_pny217-B39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejpain.2005.02.002","article-title":"Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice","volume":"9","author":"K\u00f6gel","year":"2005","journal-title":"Eur J Pain"},{"issue":"2","key":"2021031606214318200_pny217-B40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpainsymman.2006.01.013","article-title":"Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine","volume":"32","author":"Mercadante","year":"2006","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"2021031606214318200_pny217-B41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1163\/156856900750229889","article-title":"Pain relief after simultaneous administration of intravenous buprenorphine and intrathecal morphine in terminally ill patients; a report of two cases","volume":"12","author":"Beltrutti","year":"2000","journal-title":"Pain Clin"},{"issue":"6","key":"2021031606214318200_pny217-B42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0952-8180(02)00397-5","article-title":"Late antinociception and lower untoward effects of concomitant intrathecal morphine and intravenous buprenorphine in humans","volume":"14","author":"Beltrutti","year":"2002","journal-title":"J Clin Anesth"},{"issue":"3","key":"2021031606214318200_pny217-B43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clinthera.2009.03.018","article-title":"Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: A randomized, double-blind, four-arm trial in adults undergoing abdominal surgery","volume":"31","author":"Oifa","year":"2009","journal-title":"Clin Ther"},{"issue":"3","key":"2021031606214318200_pny217-B44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jpain.2008.10.003","article-title":"Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients","volume":"10","author":"Hay","year":"2009","journal-title":"J Pain"},{"issue":"2","key":"2021031606214318200_pny217-B45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0376-8716(00)00200-3","article-title":"Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent","volume":"63","author":"Compton","year":"2001","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"2021031606214318200_pny217-B46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pain.2005.11.005","article-title":"Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations","volume":"120","author":"Athanasos","year":"2006","journal-title":"Pain"},{"issue":"8","key":"2021031606214318200_pny217-B47","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.arth.2016.01.032","article-title":"Total joint arthroplasty in patients taking methadone or buprenorphine\/naloxone preoperatively for prior heroin addiction: A prospective matched cohort study","volume":"31","author":"Hansen","year":"2016","journal-title":"J Arthroplasty"},{"issue":"5","key":"2021031606214318200_pny217-B48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/ADM.0000000000000339","article-title":"Comparison of post-cesarean section opioid analgesic requirements in women with opioid use disorder treated with methadone or buprenorphine","volume":"11","author":"Vilkins","year":"2017","journal-title":"J Addict Med"},{"issue":"1","key":"2021031606214318200_pny217-B49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/pm\/pny025","article-title":"Buprenorphine maintenance subjects are hyperalgesic and have no antinociceptive response to a very high morphine dose","volume":"20","author":"Athanasos","year":"2018","journal-title":"Pain Med"},{"issue":"5","key":"2021031606214318200_pny217-B50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0310057X1103900505","article-title":"Acute pain management in opioid-tolerant patients: A growing challenge","volume":"39","author":"Huxtable","year":"2011","journal-title":"Anaesth Intensive Care"},{"key":"2021031606214318200_pny217-B51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2014.10.010","article-title":"Co-morbid pain and opioid addiction: Long term effect of opioid maintenance on acute pain","volume":"145","author":"Wachholtz","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2021031606214318200_pny217-B52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/bjaed\/mkw049","article-title":"Perioperative management of opioid-tolerant patients","volume":"17","author":"Simpson","year":"2017","journal-title":"BJA Educ"},{"issue":"2","key":"2021031606214318200_pny217-B53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3959(94)00168-E","article-title":"Acute pain management in patients with prior opioid consumption: A case-controlled retrospective review","volume":"61","author":"Rapp","year":"1995","journal-title":"Pain"},{"issue":"1","key":"2021031606214318200_pny217-B54","first-page":"E1","article-title":"Buprenorphine formulations: Clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures","volume":"21","author":"Jonan","year":"2018","journal-title":"Pain Physician"},{"issue":"3","key":"2021031606214318200_pny217-B55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/ACO.0000000000000052","article-title":"The perioperative management of patients maintained on medications used to manage opioid addiction","volume":"27","author":"Bryson","year":"2014","journal-title":"Curr Opin Anaesthesiol"},{"issue":"8","key":"2021031606214318200_pny217-B56","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/pme.12135","article-title":"Acute pain control challenges with buprenorphine\/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: A case report and review","volume":"14","author":"McCormick","year":"2013","journal-title":"Pain Med"},{"issue":"9","key":"2021031606214318200_pny217-B57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12630-014-0193-y","article-title":"Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone(R) for chronic pain: A case report","volume":"61","author":"Huang","year":"2014","journal-title":"Can J Anaesth"},{"issue":"8","key":"2021031606214318200_pny217-B58","doi-asserted-by":"crossref","first-page":"1655.e3","DOI":"10.1016\/j.ajem.2011.07.024","article-title":"Buprenorphine\/naloxone inhibition of remifentanil procedural sedation","volume":"30","author":"Gilmore","year":"2012","journal-title":"Am J Emerg Med"},{"issue":"3","key":"2021031606214318200_pny217-B59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5055\/jom.2009.0018","article-title":"Dexmedetomidine as a novel therapeutic for postoperative pain in a patient treated with buprenorphine","volume":"5","author":"Brummett","year":"2009","journal-title":"J Opioid Manage"},{"issue":"4","key":"2021031606214318200_pny217-B60","doi-asserted-by":"crossref","first-page":"657e","DOI":"10.1097\/PRS.0b013e31828277bd","article-title":"The clinical conundrum of perioperative pain management in patients with opioid dependence: Lessons from two cases","volume":"131","author":"Israel","year":"2013","journal-title":"Plast Reconstr Surg"},{"issue":"250","key":"2021031606214318200_pny217-B61","first-page":"1000250","article-title":"Perioperative pain management for patients on chronic buprenorphine: A case report","volume":"3","author":"Chern","year":"2013","journal-title":"J Anesth Clin Res"},{"issue":"2","key":"2021031606214318200_pny217-B62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/0310057X1304100212","article-title":"Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy","volume":"41","author":"Macintyre","year":"2013","journal-title":"Anaesth Intensive Care"},{"issue":"5","key":"2021031606214318200_pny217-B63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MJT.0b013e3181be0804","article-title":"Effectiveness of full agonist opioids in patients stabilized on buprenorphine undergoing major surgery: A case series","volume":"17","author":"Kornfeld","year":"2010","journal-title":"Am J Ther"},{"issue":"24","key":"2021031606214318200_pny217-B64","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"New Engl J Med"},{"issue":"3","key":"2021031606214318200_pny217-B65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00952990902825413","article-title":"Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy","volume":"35","author":"Jones","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"2021031606214318200_pny217-B66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/10550490600626721","article-title":"Post-cesarean pain management of patients maintained on methadone or buprenorphine","volume":"15","author":"Jones","year":"2006","journal-title":"Am J Addict"},{"issue":"9","key":"2021031606214318200_pny217-B67","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejpain.2010.03.002","article-title":"Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy","volume":"14","author":"Meyer","year":"2010","journal-title":"Eur J Pain"},{"issue":"2","key":"2021031606214318200_pny217-B68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1360-0443.2008.02455.x","article-title":"Buprenorphine tapering schedule and illicit opioid use","volume":"104","author":"Ling","year":"2009","journal-title":"Addiction"},{"key":"2021031606214318200_pny217-B69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"2021031606214318200_pny217-B70","doi-asserted-by":"crossref","first-page":"16.","DOI":"10.1007\/s11916-016-0549-9","article-title":"New pain management options for the surgical patient on methadone and buprenorphine","volume":"20","author":"Sen","year":"2016","journal-title":"Curr Pain Headache Rep"},{"issue":"12","key":"2021031606214318200_pny217-B71","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamapsychiatry.2013.2216","article-title":"A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers","volume":"70","author":"Sigmon","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2021031606214318200_pny217-B72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0376-8716(03)00071-1","article-title":"Cessation of methadone maintenance treatment using buprenorphine: Transfer from methadone to buprenorphine and subsequent buprenorphine reductions","volume":"71","author":"Breen","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"2021031606214318200_pny217-B73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","article-title":"Buprenorphine duration of action: Mu-opioid receptor availability and pharmacokinetic and behavioral indices","volume":"61","author":"Greenwald","year":"2007","journal-title":"Biol Psychiatry"},{"key":"2021031606214318200_pny217-B74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2021031606214318200_pny217-B75","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00213-005-0023-6","article-title":"Buprenorphine\/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers","volume":"181","author":"Comer","year":"2005","journal-title":"Psychopharmacology"},{"issue":"5","key":"2021031606214318200_pny217-B76","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.mjt.0000160935.62883.ff","article-title":"Sublingual buprenorphine is effective in the treatment of chronic pain syndrome","volume":"12","author":"Malinoff","year":"2005","journal-title":"Am J Ther"},{"issue":"1\u20133","key":"2021031606214318200_pny217-B77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2006.01.022","article-title":"Reversibility of opioid receptor occupancy of buprenorphine in vivo","volume":"534","author":"Englberger","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2021031606214318200_pny217-B78","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpain.2015.12.008","article-title":"Management of postoperative pain: A clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council","volume":"17","author":"Chou","year":"2016","journal-title":"J Pain"},{"issue":"18","key":"2021031606214318200_pny217-B79","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1001\/jama.290.18.2455","article-title":"Efficacy of postoperative epidural analgesia: A meta-analysis","volume":"290","author":"Block","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"2021031606214318200_pny217-B80","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1213\/01.ANE.0000181289.09675.7D","article-title":"Does continuous peripheral nerve block provide superior pain control to opioids? A meta-analysis","volume":"102","author":"Richman","year":"2006","journal-title":"Anesth Analg"},{"issue":"5","key":"2021031606214318200_pny217-B81","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/00000542-200511000-00023","article-title":"Efficacy of postoperative patient-controlled and continuous infusion epidural analgesia versus intravenous patient-controlled analgesia with opioids: A meta-analysis","volume":"103","author":"Wu","year":"2005","journal-title":"Anesthesiology"},{"issue":"3","key":"2021031606214318200_pny217-B82","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cpm.2008.02.003","article-title":"Non-pharmacologic pain management intervention","volume":"25","author":"Adams","year":"2008","journal-title":"Clin Podiatr Med Surg"},{"issue":"4","key":"2021031606214318200_pny217-B83","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ejpain.2011.08.008","article-title":"Peripartum pain management in opioid dependent women","volume":"16","author":"H\u00f6flich","year":"2012","journal-title":"Eur J Pain"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/20\/7\/1395\/36609679\/pny217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/20\/7\/1395\/36609679\/pny217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T02:25:34Z","timestamp":1615861534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/20\/7\/1395\/5222647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":83,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,11,30]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pny217","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2018,11,30]]}}}